Nautilus Biotechnology, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Nautilus Biotechnology, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-27.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 63% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-13.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 52% of Healthcare companies in United States.
Cash Cushion Ratio
+18%Cash, after subtracting all debt, equals 18% of its market value (net cash).
Higher than 60% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Nautilus Biotechnology, Inc. made a loss over the last year. Nautilus Biotechnology, Inc. owes $0.20 for every $1 it owns. Nautilus Biotechnology, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossNautilus Biotechnology, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.14The share price is 3.14 times Nautilus Biotechnology, Inc.'s book value per share, higher than 58% of Healthcare companies in United States.
Market cap
$412 MThe total market value of all of Nautilus Biotechnology, Inc.'s shares at today's price (share price × number of shares), larger than 52% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$131 MWhat Nautilus Biotechnology, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.03Net worth divided by the number of shares. The share price of $3.24 is 3.1 times this, which is the P/B above.
Return on equity (ROE)
-36.2%Nautilus Biotechnology, Inc. lost 36.2% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
Owes vs Owns
0.20×Nautilus Biotechnology, Inc. owes $0.20 for every $1 it owns (low), lower than 73% of Healthcare companies in United States.
Dividend yield
NoneNautilus Biotechnology, Inc. does not currently pay a dividend.
Profit growth
LossNautilus Biotechnology, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashNautilus Biotechnology, Inc. held $73 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Nautilus Biotechnology, Inc.: $412 M ÷ $131 M (30 Jun 2026) = 3.1.
What is Nautilus Biotechnology, Inc.'s return on equity?
Nautilus Biotechnology, Inc. lost 36.2% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
How much does Nautilus Biotechnology, Inc. owe compared with what it owns?
Nautilus Biotechnology, Inc. owes $0.20 for every $1 it owns (low), lower than 73% of Healthcare companies in United States.
Does Nautilus Biotechnology, Inc. pay a dividend?
No. Nautilus Biotechnology, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.